To obtain access to any datasets listed on this site, you must first receive approval from NIDA Datashare's Data Access Committee (DAC).

Please submit your request by sending your request to NIDA_Datashare_DAC@nih.gov along with the following information:

Your name, title, and organization
Study Number and Study Title
The specific dataset(s) you are requesting
The intended use or purpose of the data
Willingness to comply with the NIDA Datashare Registration Agreement

Once your request is reviewed, you will receive instructions on how to proceed.

Thank you for your cooperation.

NIDA-CTO-0008

Division

DTMC

HEAL Study

Investigator(s)

Richard Rawson, Ph.D.

Title

Phase 2, Double-Blind Placebo-Controlled Trial Of Bupropion for the Treatment of Methamphetamine Dependence

Short Description

The purpose of this study is to assess the efficacy and safety of bupropion in reducing methamphetamine use in subjects with methamphetamine dependence.

Release Date

May 07, 2018

Description

A double-blind, placebo-controlled, parallel-group design study in which 100 subjects will be randomly assigned to placebo or bupropion for 12 weeks with follow-up assessments 4 weeks following treatment. Adaptive randomization will be used to balance treatment groups based on gender.

Keywords

Assessments

Addiction Severity Index Lite

Brief Substance Craving Scale

Clinical Global Impression Scales

Hamilton – Depression Rating Scale

HIV Risk-Taking Behaviour Scale

Methamphetamine Withdrawal Questionnaire